Abstract | OBJECTIVES: METHODS: Treatment-emergent adverse events (TEAEs) and laboratory data from five randomised, placebo- or active-controlled phase III trials of upadacitinib for patients with RA were analysed and summarised. Exposure-adjusted event rates are shown for placebo (three trials; 12/14 weeks), methotrexate (two trials; mean exposure: 36 weeks), adalimumab (one trial; mean exposure: 42 weeks), upadacitinib 15 mg (five trials; mean exposure: 53 weeks) and upadacitinib 30 mg (four trials; mean exposure: 59 weeks). RESULTS: CONCLUSION: TRIAL REGISTRATION NUMBERS: SELECT-EARLY: NCT02706873; SELECT-NEXT: NCT02675426; SELECT-COMPARE: NCT02629159; SELECT-MONOTHERAPY: NCT02706951; SELECT-BEYOND: NCT02706847.
|
Authors | Stanley B Cohen, Ronald F van Vollenhoven, Kevin L Winthrop, Cristiano A F Zerbini, Yoshiya Tanaka, Louis Bessette, Ying Zhang, Nasser Khan, Barbara Hendrickson, Jeffrey V Enejosa, Gerd R Burmester |
Journal | Annals of the rheumatic diseases
(Ann Rheum Dis)
Vol. 80
Issue 3
Pg. 304-311
(03 2021)
ISSN: 1468-2060 [Electronic] England |
PMID | 33115760
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
Chemical References |
- Antirheumatic Agents
- Heterocyclic Compounds, 3-Ring
- upadacitinib
- Adalimumab
- Methotrexate
|
Topics |
- Adalimumab
(adverse effects)
- Antirheumatic Agents
(adverse effects)
- Arthritis, Rheumatoid
(chemically induced, drug therapy)
- Double-Blind Method
- Drug Therapy, Combination
- Herpes Zoster
(chemically induced, epidemiology)
- Heterocyclic Compounds, 3-Ring
(adverse effects)
- Humans
- Methotrexate
(adverse effects)
- Treatment Outcome
- Venous Thromboembolism
(chemically induced)
|